PREVENTION OR TREATMENT OF GOUT OR URIC ACID DISEASE
Patent Information
- Application Number
- MA41431
- Authority / Receiving Office
- MA · MA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-04-30
- Filing Date
- 2016-01-28
- Publication Date
- 2017-12-06
- Estimated Expiration
- 2036-01-28
AI Technical Summary
Current treatments for gout and hyperuricemia are limited in efficacy and are associated with adverse side effects, and there is a need for new agents that can effectively reduce uric acid levels and alleviate inflammation.
A class of xanthine compounds, specifically compounds of formula (I) and their pharmaceutically acceptable salts or solvates, are used to reduce uric acid levels and inhibit inflammation, thereby treating or preventing hyperuricemia, gout, gouty inflammations, pain, and uric acid nephropathy.
The xanthine compounds significantly reduce uric acid levels and alleviate inflammatory responses, effectively treating or preventing gout, gouty inflammations, pain, and uric acid nephropathy, while also reducing the risk of associated conditions like hypertension, diabetes, and kidney injury.